Tecentriq-话题@MedSci

#Tecentriq#

40篇内容 | 964人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1509580, encodeId=d6c9150958069, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, objectType=article, longId=181787, objectId=0d52181e8763, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d52181e8763, replyNumber=0, likeNumber=25, createdTime=2019-10-24, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d52181e8763, moduleTitle=罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d52181e8763)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509579, encodeId=ad7e15095e900, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, objectType=article, longId=180569, objectId=13a6180569e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a6180569e0, replyNumber=0, likeNumber=34, createdTime=2019-10-07, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a6180569e0, moduleTitle=2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a6180569e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509578, encodeId=325115095e88a, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, objectType=article, longId=180564, objectId=58f6180564c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58f6180564c6, replyNumber=0, likeNumber=41, createdTime=2019-10-07, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58f6180564c6, moduleTitle=英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58f6180564c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509577, encodeId=9e4815095e78d, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=20, createdTime=2019-09-29, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509576, encodeId=cfa915095e6c0, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, objectType=article, longId=178551, objectId=036a1e8551e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=036a1e8551e1, replyNumber=0, likeNumber=37, createdTime=2019-09-03, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=036a1e8551e1, moduleTitle=欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=036a1e8551e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509575, encodeId=e22215095e5fe, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, objectType=article, longId=177619, objectId=7d301e761945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d301e761945, replyNumber=0, likeNumber=29, createdTime=2019-08-16, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d301e761945, moduleTitle=加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d301e761945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509574, encodeId=58dd15095e46e, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, objectType=article, longId=177126, objectId=a2121e71269e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2121e71269e, replyNumber=0, likeNumber=27, createdTime=2019-08-09, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2121e71269e, moduleTitle=罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2121e71269e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509573, encodeId=d88e15095e318, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=研发日报丨一线治疗NSCLC！罗氏Tecentriq组合方案获CHMP推荐, objectType=article, longId=176562, objectId=1a791e656255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a791e656255, replyNumber=0, likeNumber=28, createdTime=2019-08-02, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a791e656255, moduleTitle=研发日报丨一线治疗NSCLC！罗氏Tecentriq组合方案获CHMP推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a791e656255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509572, encodeId=009715095e2af, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, objectType=article, longId=165339, objectId=4a3216533980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a3216533980, replyNumber=0, likeNumber=36, createdTime=2019-05-05, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a3216533980, moduleTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a3216533980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509571, encodeId=4a5a15095e161, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, objectType=article, longId=163455, objectId=500616345538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500616345538, replyNumber=0, likeNumber=30, createdTime=2019-04-04, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500616345538, moduleTitle=AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500616345538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509570, encodeId=b67115095e0cc, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, objectType=article, longId=162148, objectId=423a1621482c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423a1621482c, replyNumber=0, likeNumber=33, createdTime=2019-03-13, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423a1621482c, moduleTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423a1621482c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509569, encodeId=45f31509569eb, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=欧盟监管机构批准罗氏的组合疗法（Tecentriq、阿瓦斯汀和化疗药)用于一线治疗肺癌, objectType=article, longId=161936, objectId=89ae161936ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89ae161936ea, replyNumber=0, likeNumber=30, createdTime=2019-03-10, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89ae161936ea, moduleTitle=欧盟监管机构批准罗氏的组合疗法（Tecentriq、阿瓦斯汀和化疗药)用于一线治疗肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89ae161936ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509568, encodeId=df39150956809, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, objectType=article, longId=153843, objectId=27431538430e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27431538430e, replyNumber=0, likeNumber=23, createdTime=2018-11-20, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27431538430e, moduleTitle=罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27431538430e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509567, encodeId=f1c1150956e47, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=FDA警告:Keytruda和Tecentriq疗效并不优于化疗 | 杨森精神分裂症药物获批上市.., objectType=article, longId=139134, objectId=012213913486, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012213913486, replyNumber=0, likeNumber=37, createdTime=2018-05-27, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012213913486, moduleTitle=FDA警告:Keytruda和Tecentriq疗效并不优于化疗 | 杨森精神分裂症药物获批上市.., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012213913486)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509566, encodeId=8df11509566cf, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=FDA对罗氏Tecentriq的一线使用给予优先审查, objectType=article, longId=137599, objectId=747413e5997a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=747413e5997a, replyNumber=0, likeNumber=14, createdTime=2018-05-10, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=747413e5997a, moduleTitle=FDA对罗氏Tecentriq的一线使用给予优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=747413e5997a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509565, encodeId=6fdf1509565df, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=不错的180度大转弯——NICE支持Roche的Tecentriq用于肺癌的治疗, objectType=article, longId=134741, objectId=0b12134e4108, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b12134e4108, replyNumber=0, likeNumber=37, createdTime=2018-04-11, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b12134e4108, moduleTitle=不错的180度大转弯——NICE支持Roche的Tecentriq用于肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b12134e4108)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509564, encodeId=c174150956411, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏公司的Tecentriq被列入英国癌症药物基金目录, objectType=article, longId=122710, objectId=81d5122e1074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81d5122e1074, replyNumber=0, likeNumber=42, createdTime=2017-12-09, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81d5122e1074, moduleTitle=罗氏公司的Tecentriq被列入英国癌症药物基金目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81d5122e1074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509563, encodeId=1b7015095630f, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌（NSCLC）, objectType=article, longId=80716, objectId=9fb980e16a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb980e16a1, replyNumber=0, likeNumber=45, createdTime=2016-10-24, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb980e16a1, moduleTitle=罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb980e16a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509562, encodeId=3975150956242, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=ASCO 2016：罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积, objectType=article, longId=70140, objectId=74afe0140e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74afe0140e6, replyNumber=0, likeNumber=0, createdTime=2016-06-08, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74afe0140e6, moduleTitle=ASCO 2016：罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74afe0140e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509561, encodeId=6a651509561ed, content=<a href='/topic/show?id=b2bd1e246ab' target=_blank style='color:#2F92EE;'>#Tecentriq#</a>, objectTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, objectType=article, longId=68717, objectId=7e3c68e17a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e3c68e17a3, replyNumber=0, likeNumber=29, createdTime=2016-05-21, rootId=0, userName=lfyang, userId=b2d810099674, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e3c68e17a3, moduleTitle=FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e3c68e17a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Tecentriq

2020-05-29

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏PD-L1单抗Tecentriq联合VEGF单抗Avastin组合治疗肝癌的III期临床成功

2019-10-24

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

2019 ESMO：PD-L1单抗Tecentriq联合化疗被证明对膀胱癌有效

2019-10-07

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

英国NICE对罗氏的PD-L1单抗Tecentriq治疗晚期乳腺癌say

2019-10-07

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2019-09-29

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

欧盟批准罗氏的PD-L1单抗Tecentriq联合紫杉醇治疗三阴性乳腺癌

2019-09-03

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

加拿大卫生部批准罗氏PD-L1单抗Tecentriq治疗小细胞肺癌，这是20年来加拿大批准治疗该疾病的新疗法

2019-08-16

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏PD-L1单抗Tecentriq与化疗药联合治疗膀胱癌III期结果喜人

2019-08-09

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

研发日报丨一线治疗NSCLC！罗氏Tecentriq组合方案获CHMP推荐

2019-08-02

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌

2019-05-05

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

AACR19：晚期三阴性乳腺癌患者经Ipatasertib与Tecentriq联合化疗的ORR高达73％

2019-04-04

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准

2019-03-13

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

欧盟监管机构批准罗氏的组合疗法（Tecentriq、阿瓦斯汀和化疗药)用于一线治疗肺癌

2019-03-10

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏向欧盟提起申请：Tecentriq与Avastin联合治疗肾细胞癌

2018-11-20

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

FDA警告:Keytruda和Tecentriq疗效并不优于化疗 | 杨森精神分裂症药物获批上市..

2018-05-27

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

FDA对罗氏Tecentriq的一线使用给予优先审查

2018-05-10

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

不错的180度大转弯——NICE支持Roche的Tecentriq用于肺癌的治疗

2018-04-11

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏公司的Tecentriq被列入英国癌症药物基金目录

2017-12-09

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌（NSCLC）

2016-10-24

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

ASCO 2016：罗氏PD-L1免疫疗法Tecentriq一线治疗晚期膀胱癌显著缩小肿瘤体积

2016-06-08

lfyang (审核中...)

前往app查看评论内容

#Tecentriq#

FDA批准PD-L1抑制剂——罗氏Tecentriq (atezolizumab)治疗尿路上皮癌

2016-05-21

科室
- - 订阅+
  - 更多科室
工具
服务